USA

News & Media

Take a closer look at what we’re doing across Teva worldwide

Our latest news

Teva’s Emrusolmin Granted U.S. FDA Fast Track Designation for Treatment of Multiple System Atrophy

Teva to Present at Morgan Stanley Global Healthcare Conference and Bank of America Global Healthcare Conference in September

Teva Announces FDA Approval and Launch of Generic Saxenda® (liraglutide injection) – First Generic GLP-1 Indicated for Weight Loss

FDA Approves Expanded Indication for AJOVY® (fremanezumab-vfrm), The First Anti-CGRP Preventive T...

Teva's Innovative Portfolio Fuels 10th Consecutive Quarter of Growth in Q2 2025; Increases 2025 R...

Teva Releases Q2 2025 Aide Memoire

Teva to Host Conference Call to Discuss Second Quarter 2025 Financial Results at 8 a.m. ET on Jul...

Final Data from Teva’s PEARL Real-World Study Reinforce the Long-term Effectiveness of AJOVY® (fr...

Teva and Fosun Pharma Enter into a Strategic Partnership to Develop Novel Anti-PD1-IL2 Therapy (T...

Teva Announces Pricing and Early Acceptance Results of its Debt Tender Offer
See all news items

Discover the world of Teva

Follow our latest feature stories with news and views from across our global organization

Discover more Discover the world of Teva

Media Resources

at the office

Media Inquiries

Contact our corporate communications.
Learn more Media Inquiries

Media Kit

Files and resources for media use only
Download Teva Media Kit Media Kit

Financial Reports

View Teva financial news on our global website.
Learn more Financial Reports

Connect with us

Teva Social Media Guidelines.
Learn more Connect with us